Sommetrics, a private company developing solutions to improve sleep health by providing innovative first-in-class products to treat sleep apnea, announced that John Frank was elected to its Board of Directors. Mr. Frank has over three decades of experience and a successful track record of developing innovative solutions and world-class organizations […]
Tag: AERSLEEP
Sommetrics Provides Update on SUPRA Clinical Trial for OSA
Sommetrics, a private company developing products and services to improve sleep health, released an update on its key accomplishments during the first quarter of 2022. Chief among these accomplishments was the Company’s advancing clinical activities aimed at obtaining FDA market clearance for its flagship product, aerSleep® II, that is targeted […]
Sommetrics Launches Pivotal Clinical Study of aerSleep II OSA Treatment Device, Raise Additional $11 Million
Sommetrics announced the launch of the pivotal clinical trial of its aerSleep® II device for the treatment of obstructive sleep apnea (OSA). This study is being conducted at 10 university and community-based sleep centers in the U.S. under an Investigational Device Exemption approved by the Food and Drug Administration. Termed the […]
Sommetrics Completes Study of New Sleep Apnea Treatment in Ethnic Japanese Subjects
Sommetrics today announced the completion of clinical study SOM-014. This trial evaluated the safety, tolerability and effectiveness of the Sommetrics aerSleep™ product in ethnic Japanese subjects with obstructive sleep apnea (OSA). This was a prospective, observational study conducted at the American Academy of Sleep Medicine accredited Sleep Lab in Kaneohe, […]
Sommetrics Selected to Present at Respiratory Innovation Summit
Sommetrics has been selected to be one of five companies to present at the airways symposium of the Respiratory Innovation Summit in Dallas on May 17, 2019. This Summit is a yearly event held in advance of the American Thoracic Society’s International meeting which brings together clinicians, innovators and investors […]







